February 28, 2025 - 02:08

ROUND ROCK, Texas, February 27, 2025—Dell Technologies has unveiled its financial results for the fourth quarter and the entire fiscal year of 2025. The company showcased robust performance, reflecting its strategic initiatives and market positioning. In the fourth quarter, Dell reported a significant increase in revenue, driven by strong demand across its product lines, particularly in cloud computing and data center solutions.
For the full fiscal year, Dell demonstrated resilience amid a challenging economic landscape, achieving impressive growth in both revenue and earnings. The company's focus on innovation and customer-centric solutions has played a pivotal role in its success.
Looking ahead, Dell has provided guidance for the first quarter and full year of fiscal 2026, indicating a positive outlook. The company aims to capitalize on emerging market trends and continue its trajectory of growth. Stakeholders and investors are optimistic about Dell's strategic direction as it prepares for the upcoming fiscal year.
May 14, 2026 - 00:55
Aeluma Announces Third Quarter Fiscal 2026 Financial ResultsAeluma, Inc., a company specializing in compound semiconductor technologies, has released its financial results for the third quarter of fiscal year 2026. The report comes alongside several major...
May 13, 2026 - 11:31
MCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives ContinueHealthcare distributor McKesson reported first-quarter earnings that missed revenue expectations, though the company continued to push ahead with margin-focused initiatives. For the quarter ending...
May 12, 2026 - 23:07
Prudential Financial Declares Quarterly Dividend on Common StockNEWARK, N.J., May 12, 2026 -- Prudential Financial, Inc. has declared a quarterly dividend of $1.40 per share on its common stock. The payment is scheduled for June 11, 2026, and will go to...
May 12, 2026 - 03:06
Cellectis Reports First Quarter 2026 Financial ResultsCellectis has announced its financial results for the first quarter of 2026, alongside updates on its clinical pipeline and preclinical research programs. The company is advancing its pivotal...